<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment strategies for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> have not been established </plain></SENT>
<SENT sid="1" pm="."><plain>We report the outcome after combination therapy with rituximab and cladribine (RC) for 8 patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treated between January 2005 and December 2006 in our hospitals </plain></SENT>
<SENT sid="2" pm="."><plain>Median patient age was 57 (range 42 approximately 73) years </plain></SENT>
<SENT sid="3" pm="."><plain>There were 4 males and 4 females </plain></SENT>
<SENT sid="4" pm="."><plain>Only 1 patient had refractory disease, while the others had untreated disease </plain></SENT>
<SENT sid="5" pm="."><plain>On the follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> international prognostic index, 4 patients were in the low-risk group, 3 in the intermediate-risk group and 1 in the high-risk group </plain></SENT>
<SENT sid="6" pm="."><plain>The median follow-up period was 36 (range 22 approximately 90) weeks </plain></SENT>
<SENT sid="7" pm="."><plain>The RC protocol consisted of intravenous rituximab at a dose of 375 mg/m (2) on day 1 and cladribine at a dose of 0.1 mg /kg per day for 2-hours on day 1 through 5 </plain></SENT>
<SENT sid="8" pm="."><plain>The median number of RC courses was 5 (range 3 approximately 8) </plain></SENT>
<SENT sid="9" pm="."><plain>The median interval between the 2 courses was 7 (range 3 approximately 26) weeks </plain></SENT>
<SENT sid="10" pm="."><plain>The overall response rate was 87.5% </plain></SENT>
<SENT sid="11" pm="."><plain>Grade 3 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> was observed in 50% patients, although G-CSF was not needed </plain></SENT>
<SENT sid="12" pm="."><plain>There was no apparent <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> or <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0019360" disease_type="Disease or Syndrome" abbrv="ZONA">Herpes zoster</z:e> was observed after treatment in 1 patient </plain></SENT>
<SENT sid="14" pm="."><plain>RC is considered highly effective and well tolerated </plain></SENT>
</text></document>